Immunohistochemical Detection of Dopamine D2 Receptors in Human Pituitary Adenomas
Overview
Authors
Affiliations
Thirty one pituitary adenomas and 3 samples of peritumoral anterior pituitary tissue were immunostained with an antibody raised against dopamine D2 receptor protein. The positive reactions were found in cell cytoplasm, a subpopulation of cell nuclei and the intratumoral blood vessels walls. As expected, the positive immunostaining was shown in cytoplasm and/or cell nuclei of all examined prolactinomas (7/7). In acromegaly the positive D2 staining occurred in 5/7 samples, in gonadotropinomas in 6/8 and in plurihormonal adenomas 2/4. The lowest expression was observed in corticotropinomas (1/5). These findings corroborate with the well known efficacy of D2 agonists in the treatment of prolactinomas and somatotropinomas, and support the rationale of the therapeutic trials with these compounds in gonadotropinomas. Moreover, the presence of D2 receptors in intratumoral blood vessels walls constitutes the possibility of the anti-angiogenic action of D2 agonists in pituitary adenomas.
Somatostatin and Somatostatin Receptors in Tumour Biology.
Kumar U Int J Mol Sci. 2024; 25(1).
PMID: 38203605 PMC: 10779198. DOI: 10.3390/ijms25010436.
The dopaminergic control of Cushing's syndrome.
Pivonello R, Pivonello C, Simeoli C, De Martino M, Colao A J Endocrinol Invest. 2022; 45(7):1297-1315.
PMID: 35460460 PMC: 9184412. DOI: 10.1007/s40618-021-01661-x.
Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.
Capatina C, Poiana C Acta Endocrinol (Buchar). 2022; 17(3):377-382.
PMID: 35342478 PMC: 8919496. DOI: 10.4183/aeb.2021.377.
Dopamine agonist-responsive Cushing's disease.
Anand G, Bink A, Beuschlein F, Schmid C BMJ Case Rep. 2019; 12(2).
PMID: 30765454 PMC: 6381956. DOI: 10.1136/bcr-2018-228045.
Dopamine Agonists for Pituitary Adenomas.
Cooper O, Greenman Y Front Endocrinol (Lausanne). 2018; 9:469.
PMID: 30186234 PMC: 6110840. DOI: 10.3389/fendo.2018.00469.